Patients' Preferences for Once-Daily Oral Versus Once-Weekly Injectable Diabetes Medications: The REVISE Study
Author(s)
Boye K*1;Ross M2;Mody R3;Konig M3, Gelhorn H4
1Eli Lilly and Company, Greenwood, IN, USA, 2Evidera, Bethesda, MD, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Evidera, Winter Park, CO, USA
OBJECTIVES: This study aimed to understand preferences of people with Type 2 Diabetes Mellitus (T2DM) for once-daily oral vs. once-weekly injectable medication options and the reasons for their preferences.
METHODS: The REVISE study, was a cross-sectional online survey of 600 participants with T2DM (n=300 UK, n=300 US) about general preferences for once-daily oral versus once-weekly injectable diabetes medications, and reasons for their preference. Participants then viewed two videos describing the administration procedures for once-weekly injectable dulaglutide and once-daily oral semaglutide which were developed based on instructions for use for each medication. Thereafter, participants indicated whether they would prefer a once-weekly injectable medication or a once-daily oral medication similar to the medications described in the videos. Participants who switched preferences were asked to identify the reasons for their decision.
RESULTS: The majority of participants were male (n=349; 58.2%), mean age 64.1 years (SD=11.3), and a mean BMI 31.9 (SD=7.5). Nearly all (n=557; 92.8%) were currently taking an oral T2DM medication, and 158 (26.3%) currently used an injectable. For initial preference, 76.5% (n=459; 95% CI: 73.1% to 79.9%) preferred a once-daily oral medication and 23.5% a once-weekly injectable (n=141; 95% CI: 20.1% to 26.9%; p<0.0001). After viewing the videos describing the product-specific administration characteristics, equal proportions of participants preferred each option (oral semaglutide administration description (n=315; 52.5%; 95% CI: 48.5% to 56.5%); dulaglutide administration description (n=285; 47.5%; 95% CI: 43.5% to 51.5%; NS p=0.2207)). The most common reason for switching preferences was the timing and steps of medication administration.
CONCLUSIONS: Several treatment related characteristics, including the route, frequency, and complexity of the treatment administration play a role in patients’ preferences for T2DM treatments and should be considered when selecting treatment.
METHODS: The REVISE study, was a cross-sectional online survey of 600 participants with T2DM (n=300 UK, n=300 US) about general preferences for once-daily oral versus once-weekly injectable diabetes medications, and reasons for their preference. Participants then viewed two videos describing the administration procedures for once-weekly injectable dulaglutide and once-daily oral semaglutide which were developed based on instructions for use for each medication. Thereafter, participants indicated whether they would prefer a once-weekly injectable medication or a once-daily oral medication similar to the medications described in the videos. Participants who switched preferences were asked to identify the reasons for their decision.
RESULTS: The majority of participants were male (n=349; 58.2%), mean age 64.1 years (SD=11.3), and a mean BMI 31.9 (SD=7.5). Nearly all (n=557; 92.8%) were currently taking an oral T2DM medication, and 158 (26.3%) currently used an injectable. For initial preference, 76.5% (n=459; 95% CI: 73.1% to 79.9%) preferred a once-daily oral medication and 23.5% a once-weekly injectable (n=141; 95% CI: 20.1% to 26.9%; p<0.0001). After viewing the videos describing the product-specific administration characteristics, equal proportions of participants preferred each option (oral semaglutide administration description (n=315; 52.5%; 95% CI: 48.5% to 56.5%); dulaglutide administration description (n=285; 47.5%; 95% CI: 43.5% to 51.5%; NS p=0.2207)). The most common reason for switching preferences was the timing and steps of medication administration.
CONCLUSIONS: Several treatment related characteristics, including the route, frequency, and complexity of the treatment administration play a role in patients’ preferences for T2DM treatments and should be considered when selecting treatment.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
CV2
Topic
Patient-Centered Research
Topic Subcategory
Stated Preference & Patient Satisfaction
Disease
Diabetes/Endocrine/Metabolic Disorders, Drugs